Humana Inc. (NYSE:HUM) Accelerates Membership Growth, Pressuring Margin Recovery Near-Term

Humana’s membership-driven top-line expansion appears set to continue, while margin recovery faces near-term pressure from operational mix and capital actions. Momentum indicators support further short-term upside but a valuation gap persists.

Recent News

On February 19, 2026 the board declared a cash dividend of $0.885 per share payable April 24, 2026. In March 2026 the company completed a $1.0 billion public offering of fixed-to-fixed junior subordinated notes, increasing debt-to-capital and providing additional liquidity for strategic operations and growth initiatives.

Technical Analysis

The ADX reads 33.64, indicating a strong trend in place; the strength gives conviction to momentum-driven price expectations tied to the membership-growth narrative and supports the view of continued directional price movement over the near term.

DI+ at 34.59 shows a dip-and-reverse (increasing), which registers as a bullish directional signal; DI- at 17.39 shows a peak-and-reverse (decreasing), which also reads bullish. Together these directional indicators favor further upside movement relative to the current valuation backdrop.

MACD stands at 13.16 with the MACD line above the signal line (10.52) and an increasing MACD_trend; the cross above the signal line constitutes a bullish momentum signal that aligns with the ADX/DI directional bias.

MRO equals 16.47 and the MRO_trend increases; because MRO is positive, price currently sits above target and carries risk of mean reversion toward fair-value ranges, which tempers the bullish momentum signals for immediate gains.

RSI at 59.24 and rising indicates constructive momentum without overbought extremes, leaving room for additional appreciation before exhaustion becomes likely; this supports a continuation scenario while monitoring for RSI moves above typical overbought thresholds.

Price structure confirms the momentum picture: last close $246.33 exceeds the 20-day average ($226.48), 50-day average ($193.04) and slightly exceeds the 200-day average ($240.50), with the 12-day EMA (price12dayEMA) rising above the 26-day EMA—an additional bullish alignment. Price sits above the 1x Bollinger upper band ($241.32), signaling short-term extension relative to recent volatility.

Volume sits modestly below the 10-day average but above the 50-day average; 42‑day and 52‑week betas (0.65 and 0.53) indicate below-market volatility, which reduces the likelihood of abrupt directional reversals but also compresses the potential amplitude of short-term moves relative to higher-beta peers.

 


Fundamental Analysis

Total revenue reached $39,648,000,000 with reported EBIT $1,788,000,000, producing an EBIT margin of 4.51%. That EBIT margin sits below the industry peer mean (6.79%) and slightly below the industry peer median (4.69%), indicating margins trail the peer mean while approximating the peer median.

YoY revenue growth reads 121.06% and the trailing revenue growth figure shows 21.94%; the company reports material membership gains that drive top-line expansion. Free cash flow of $1,133,000,000 yields 4.69%, above the industry peer mean of 2.47%, supporting cash generation relative to peers.

EPS came in at $10.31 versus an estimate of $10.20, an EPS surprise of approximately 1.08%; forward EPS sits at $3.82 producing a forward PE of 52.34 versus a current PE of 19.53, reflecting market expectations for lower near-term earnings per share.

Balance-sheet and coverage metrics remain supportive: debt-to-assets at 25.31% falls below the industry peer mean of 29.43%; interest coverage ratio equals 9.26, above the industry peer mean of 5.43, limiting short-term solvency risk while the company absorbs recent capital-market activity. Dividend payout ratio sits near 9.02% with a dividend yield of 0.44% and available cash plus short-term investments of $21,965,000,000 provide liquidity for operational and strategic uses.

QoQ and YoY notes: EBIT margin moved -269.55% QoQ and -21.76% YoY as reported; return-on-equity decreased QoQ by 241.59% and YoY by 8.92%; use caution integrating large QoQ swings into trend interpretation because membership and benefit timing can produce quarter-level distortion. The company reaffirmed individual Medicare Advantage membership growth guidance for 2026, which underpins the top-line trajectory.

WMDST values the stock as under-valued based on free cash flow yield above the industry peer mean, strong interest coverage, and membership-driven revenue growth that supports near-term cash generation despite margins below the peer mean.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-04-29
NEXT REPORT DATE: 2026-07-29
CASH FLOW  Begin Period Cash Flow 4.2 B
 Operating Cash Flow 1.3 B
 Capital Expenditures -121.00 M
 Change In Working Capital -215.00 M
 Dividends Paid -107.00 M
 Cash Flow Delta 751.0 M
 End Period Cash Flow 5.0 B
 
INCOME STATEMENT REVENUE
 Total Revenue 39.6 B
 Forward Revenue 3.8 B
COSTS
 Cost Of Revenue
 Depreciation 183.0 M
 Depreciation and Amortization 194.0 M
 Research and Development
 Total Operating Expenses 38.1 B
PROFITABILITY
 Gross Profit
 EBITDA
 EBIT 1.8 B
 Operating Income
 Interest Income
 Interest Expense 193.0 M
 Net Interest Income -193.00 M
 Income Before Tax 1.6 B
 Tax Provision 395.0 M
 Tax Rate 24.765 %
 Net Income 1.2 B
 Net Income From Continuing Operations 1.2 B
EARNINGS
 EPS Estimate 10.20
 EPS Actual 10.31
 EPS Difference 0.11
 EPS Surprise 1.078 %
 Forward EPS 3.82
 
BALANCE SHEET ASSETS
 Total Assets 55.3 B
 Intangible Assets 10.5 B
 Net Tangible Assets 8.1 B
 Total Current Assets
 Cash and Short-Term Investments 22.0 B
 Cash 5.0 B
 Net Receivables 5.2 B
 Inventory
 Long-Term Investments
LIABILITIES
 Accounts Payable 19.2 B
 Short-Term Debt 1.7 B
 Total Current Liabilities
 Net Debt 9.0 B
 Total Debt 14.0 B
 Total Liabilities 36.6 B
EQUITY
 Total Equity 18.6 B
 Retained Earnings 30.2 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 154.75
 Shares Outstanding 120.061 M
 Revenue Per-Share 330.23
VALUATION
 Market Capitalization 24.2 B
 Enterprise Value 16.2 B
 Enterprise Multiple
Enterprise Multiple QoQ
Enterprise Multiple YoY
Enterprise Multiple IPRWA
 EV/R 0.409
CAPITAL STRUCTURE
 Asset To Equity 2.975
 Asset To Liability 1.509
 Debt To Capital 0.43
 Debt To Assets 0.253
Debt To Assets QoQ 0.091 %
Debt To Assets YoY -3.112 %
Debt To Assets IPRWA high: 0.384
median: 0.31
mean: 0.294
HUM: 0.253
low: 0.009
 Debt To Equity 0.753
Debt To Equity QoQ 7.509 %
Debt To Equity YoY 0.471 %
Debt To Equity IPRWA high: 1.595
median: 1.011
mean: 0.886
HUM: 0.753
low: 0.009
PRICE-BASED VALUATION
 Price To Book (P/B) 1.301
Price To Book QoQ -21.685 %
Price To Book YoY -28.793 %
Price To Book IPRWA high: 23.876
mean: 4.334
HUM: 1.301
median: 1.281
low: 0.496
 Price To Earnings (P/E) 19.527
Price To Earnings QoQ -131.792 %
Price To Earnings YoY -15.846 %
Price To Earnings IPRWA high: 165.793
mean: 52.98
median: 30.133
HUM: 19.527
low: -50.098
 PE/G Ratio -0.054
 Price To Sales (P/S) 0.61
Price To Sales QoQ -32.417 %
Price To Sales YoY -39.634 %
Price To Sales IPRWA high: 22.583
mean: 5.068
low: 0.988
median: 0.988
HUM: 0.61
FORWARD MULTIPLES
Forward P/E 52.337
Forward PE/G -0.145
Forward P/S 6.332
EFFICIENCY OPERATIONAL
 Operating Leverage -13.981
ASSET & SALES
 Asset Turnover Ratio 0.761
Asset Turnover Ratio QoQ 15.429 %
Asset Turnover Ratio YoY 15.434 %
Asset Turnover Ratio IPRWA high: 1.061
HUM: 0.761
median: 0.397
mean: 0.36
low: 0.06
 Receivables Turnover 9.342
Receivables Turnover Ratio QoQ -14.466 %
Receivables Turnover Ratio YoY 4.194 %
Receivables Turnover Ratio IPRWA HUM: 9.342
high: 5.509
median: 5.509
mean: 4.305
low: 0.924
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 9.768
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 9.768
Cash Conversion Cycle Days QoQ 16.912 %
Cash Conversion Cycle Days YoY -4.025 %
Cash Conversion Cycle Days IPRWA high: 83.862
mean: 26.233
median: 17.779
HUM: 9.768
low: -39.8
CAPITAL DEPLOYMENT
 Cash Conversion Ratio
 CapEx To Revenue -0.003
 CapEx To Depreciation -0.661
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 30.9 B
 Net Invested Capital 32.6 B
 Invested Capital 32.6 B
 Net Tangible Assets 8.1 B
 Net Working Capital
LIQUIDITY
 Cash Ratio
 Current Ratio
Current Ratio QoQ
Current Ratio YoY
Current Ratio IPRWA
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA
 Cost Of Debt 1.102 %
 Interest Coverage Ratio 9.264
Interest Coverage Ratio QoQ -256.368 %
Interest Coverage Ratio YoY -19.92 %
Interest Coverage Ratio IPRWA high: 18.797
HUM: 9.264
median: 6.088
mean: 5.426
low: -86.056
 Operating Cash Flow Ratio
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO)
DIVIDENDS
 Dividend Coverage Ratio 11.084
 Dividend Payout Ratio 0.09
 Dividend Rate 0.89
 Dividend Yield 0.004
PERFORMANCE GROWTH
 Asset Growth Rate 13.026 %
 Revenue Growth 21.938 %
Revenue Growth QoQ -5450.732 %
Revenue Growth YoY 121.06 %
Revenue Growth IPRWA high: 21.958 %
HUM: 21.938 %
mean: -2.532 %
median: -4.983 %
low: -15.485 %
 Earnings Growth -360.354 %
Earnings Growth QoQ 62.159 %
Earnings Growth YoY -43.35 %
Earnings Growth IPRWA high: 180.0 %
mean: 86.097 %
median: 4.423 %
low: -83.333 %
HUM: -360.354 %
MARGINS
 Gross Margin
Gross Margin QoQ
Gross Margin YoY
Gross Margin IPRWA
 EBIT Margin 4.51 %
EBIT Margin QoQ -269.549 %
EBIT Margin YoY -21.756 %
EBIT Margin IPRWA high: 22.167 %
mean: 6.794 %
median: 4.692 %
HUM: 4.51 %
low: -60.342 %
 Return On Sales (ROS)
Return On Sales QoQ
Return On Sales YoY
Return On Sales IPRWA
CASH FLOW
 Free Cash Flow (FCF) 1.1 B
 Free Cash Flow Yield 4.687 %
Free Cash Flow Yield QoQ -174.15 %
Free Cash Flow Yield YoY 543.819 %
Free Cash Flow Yield IPRWA HUM: 4.687 %
high: 3.426 %
median: 3.426 %
mean: 2.465 %
low: -2.575 %
 Free Cash Growth -161.111 %
Free Cash Growth QoQ -49.93 %
Free Cash Growth YoY 19.693 %
Free Cash Growth IPRWA high: 422.536 %
median: 30.468 %
mean: 2.945 %
HUM: -161.111 %
low: -318.97 %
 Free Cash To Net Income 0.955
 Cash Flow Margin 7.491 %
 Cash Flow To Earnings 2.504
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 2.277 %
Return On Assets QoQ -241.078 %
Return On Assets YoY -10.846 %
Return On Assets IPRWA high: 6.035 %
HUM: 2.277 %
mean: 1.641 %
median: 1.162 %
low: -2.254 %
 Return On Capital Employed (ROCE)
 Return On Equity (ROE) 0.064
Return On Equity QoQ -241.593 %
Return On Equity YoY -8.918 %
Return On Equity IPRWA high: 0.207
HUM: 0.064
mean: 0.052
median: 0.038
low: -0.065
 DuPont ROE 6.545 %
 Return On Invested Capital (ROIC) 4.13 %
Return On Invested Capital QoQ -290.235 %
Return On Invested Capital YoY -8.1 %
Return On Invested Capital IPRWA high: 5.126 %
HUM: 4.13 %
median: 2.517 %
mean: 2.203 %
low: -10.552 %

Six-Week Outlook

Momentum favors a continuation of the recent advance over the next six weeks: bullish directional indicators (DI+/DI-), a rising MACD above its signal line, and price above key short- and medium-term averages support further upside potential. Offsetting this constructive setup, a positive MRO signals price sits above target and could trigger a pullback or consolidation, especially if volume fails to accelerate.

Monitor for confirmation: sustained price above the 20-day average and maintenance of MACD above its signal line would strengthen the continuation case; a move back inside the 1x Bollinger band or a falling RSI would increase the probability of a corrective phase toward the 20–50‑day averages. Given below-market beta, expect measured, lower-volatility swings rather than abrupt directional shifts.

About Humana Inc.

Humana Inc. (NYSE:HUM) delivers comprehensive healthcare solutions, headquartered in Louisville, Kentucky. Established in 1961, Humana has grown into a prominent entity in the health insurance sector. The company operates through two primary segments: Insurance and CenterWell. Humana provides a broad array of medical and specialty insurance products, serving individuals, employer groups, and military personnel. The company collaborates with the Centers for Medicare and Medicaid Services to manage prescription drug programs and partners with various states to offer Medicaid and long-term support services. Beyond traditional insurance, Humana offers dental, vision, and life insurance, along with administrative services. Humana emphasizes integrated care solutions, running pharmacies and senior-focused primary care centers. Through its CenterWell segment, Humana extends home health and hospice services, enhancing care continuity for its members. The company’s diverse distribution channels, including digital platforms, brokers, and sales representatives, ensure personalized and effective healthcare solutions for its members. Humana’s commitment to improving health outcomes is evident in its innovative approach and comprehensive service offerings.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.